Q2 FY24 Financial Highlights
Innovation and Quality
R&D pivoting towards complex generics and
biosimilars
Substantial Capabilities to become CGx powerhouse
•
•
Inhalation: Global presence with end to end capabilities
of MDIs, DPIs, Soft-Mist Inhalers, Nasal Sprays and
Nebules
Injectables: Robust suite of depot, liposomal, peptide and
iron injectable products in development
Biosimilars: A fully vertically-integrated commercial-stage
company with regulated market approvals and launches.
Long term Goals
Complex Generics: Launches in Regulated Markets by 2028
20 complex product launches in the areas of inhalation,
injectables, amongst others
Biosimilar and Novel Complex Products: By 2028
Complete 3 biosimilar filings in regulated markets
Launch 10 novel complex pipeline products in India
Achieve Best-in-Class Quality
Recent Track Record
Successful outcomes in last 4 inspections
Successful completion of FDA inspection at Vizag
•
•
EIR for Nagpur Unit-2;
•
EIR for Mandideep Unit-1
•
EIR for Pithampur Unit-2 with VAI status
2 Warning Letter affected sites:
Tarapur and Mandideep Unit-1 resolution underway
Long term Goals
Regulatory Compliance: Targeting all sites to have
satisfactory compliance status by FY25
LUPIN
Conduct Quality Audits of suppliers regularly and provide
mandatory cGMP Training to all relevant employees
11View entire presentation